During the course of the trial (median follow-up 1.2 years), 100 participants became HIV infected : 64 in the placebo arm and 36 of those receiving the active drug.
In the tenofovir/emtricitabine group, the study drug was detected in the blood of 51% of those who remained HIV uninfected, but in only 9% of those who became infected.